Stryker receives FDA clearance for Sonopet 3: stock pre-market at EUR 262.45, plus 0.63 percent
Published on 10/16/2026 at 07:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSProduct development and trading outlook
- Stryker announced FDA 510(k) clearance for Sonopet 3 on October 14, 2026.
- Stryker stock trades pre-market at EUR 262.45 at 7:41 a.m. CEST at Lang & Schwarz on October 16, 2026, 0.63 percent above the Xetra close of October 15, 2026.
- The first clinical cases using Sonopet 3 are expected to begin in October 2026.
- The platform includes 2 named technologies, RISE and Pulse Control.
Stryker said on October 14, 2026, that the U.S. Food and Drug Administration had granted 510(k) clearance for Sonopet 3, its latest ultrasonic bone and soft tissue removal platform. The company said the system was developed with input from hundreds of surgeons and includes RISE and Pulse Control technologies. Stryker said first clinical cases are expected to begin in October, with a full commercial launch anticipated later this fall.
Pre-market trading
Stryker stock trades at Lang & Schwarz at EUR 262.45 on October 16, 2026, at 7:41 a.m. CEST, up 0.63 percent versus the Xetra close of October 15, 2026, at EUR 260.80. The bid was EUR 261.50 and the ask was EUR 263.40. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Stryker stock.
What matters today
Stryker’s October 14, 2026, announcement said the first clinical cases using Sonopet 3 are expected to begin in October 2026. The current price is EUR 1.65, or 0.63 percent, above the October 15, 2026, Xetra close. Sonopet 3 provides access to 2 named technologies, RISE and Pulse Control, while the company expects a full commercial launch later this fall.
Market context: Market report S&P 500.
